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Solifenacin and Tolterodine are Equally Effective in
the Treatment of Overactive Bladder Symptoms
Chen-Hsun Ho,1,3 Ting-Chen Chang,2 Ho-Hsiung Lin,2 Shih-Ping Liu,1
Kuo-How Huang,1 Hong-Jeng Yu1*
Background/Purpose: Various antimuscarinic agents have been developed for the treatment of overactive
bladder (OAB). More data comparing these agents are still required. This study evaluated the efficacy and
safety of solifenacin and tolterodine in Taiwanese patients with OAB symptoms.
Methods: This was a prospective, randomized, open-label study. A total of 75 patients (25 men and 
50 women) with OAB symptoms were randomized to treatment with solifenacin (n = 39) or tolterodine
(n = 36). Efficacy and safety variables were assessed and compared with the baseline and between the 
two groups.
Results: At week 12, solifenacin and tolterodine demonstrated equal efficacy in reducing the number 
of micturition (–2.56 ± 3.31 vs. –2.44 ± 4.56, p = 0.58), urgency (–1.70 ± 3.07 vs. –1.15 ± 2.68, p = 0.37) and
incontinence (–2.79 ± 2.82 vs. –4.67 ± 9.29, p = 0.28) episodes per 24 hours. There was no difference in
improvement of the quality of life. The patient and physician assessments of treatment benefit were not
statistically different for solifenacin and tolterodine (p = 0.23 and p = 0.52, respectively), with the majority
showing benefits in both groups. The incidence of major adverse events, including dry mouth (18.0% vs.
8.3%, p = 0.31) and constipation (12.8% vs. 2.8%, p = 0.20) was not significantly different. Compared with
baseline, the severity of dry mouth did not increase in either group.
Conclusion: Both solifenacin and tolterodine are effective in treating key OAB symptoms, including uri-
nary frequency, urgency and incontinence in the Taiwanese population. Both medications are comparably
effective and safe, with the most common adverse effects being dry mouth and constipation.
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Overactive bladder (OAB) is defined by the Inter-
national Continence Society as a syndrome that
comprises urgency, with or without incontinence,
usually accompanied by frequency and nocturia.1
An epidemiological survey of 1581 Taiwanese
women has demonstrated that OAB affects 18.6%
of this population,2 and the prevalence rate is sim-
ilar to that of western populations.3,4 In addition
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to its high prevalence rate, several lines of evidence
have shown that OAB adversely affects quality 
of life5 and is associated with an increased risk 
of urinary tract infection, skin infection, and fall
injury.6,7 These health-related consequences war-
rant appropriate management of OAB.
Treatment for OAB includes behavioral, phar-
macological, and surgical therapy. Among these
choices, antimuscarinic agents remain the main-
stay of treatment.8 There are five subtypes of mus-
carinic receptors (M1–M5) throughout the human
body. In the urinary bladder, although M2 recep-
tors predominate in number, normal bladder con-
traction is mainly mediated by stimulation of M3
receptors,9 which are also the target of antimus-
carinic agents. By blocking the muscarinic recep-
tors, antimuscarinic agents inhibit the abnormal
bladder contractions (detrusor overactivity) and
subsequently reduce OAB symptoms. However,
antimuscarinic agents also act on other muscarinic
receptors throughout the body and therefore cause
adverse effects, including dry mouth, constipa-
tion, drowsiness, and blurred vision. Clinically,
it is these adverse effects that limit the use of 
antimuscarinics.
In recent decades, several new compounds have
been developed to reduce these unfavorable ad-
verse effects. Tolterodine was the first agent in-
troduced for this purpose. It is bladder-selective
and has been shown in animal studies to have a
greater affinity in the bladder than in the salivary
glands.10 Clinically, tolterodine has been demon-
strated to have less side effects than other anti-
muscarinic agent.11 A newer antimuscarinic agent,
solifenacin, has also proved to be bladder-selective
and even M3-receptor-selective. Clinical trials have
shown that solifenacin is effective in the treatment
of OAB and is generally well tolerated.12
Although several studies have compared both
medications in western populations,13,14 to the
best of our knowledge, a comparison based on a
Taiwanese population has not been reported. For
this purpose, we conducted a prospective and
randomized trial to compare the efficacy and
safety of 5 mg solifenacin once daily and 4 mg
tolterodine once daily.
Patients and Methods
Subjects were enrolled from the outpatient clin-
ics of Urology, and Obstetrics and Gynecology at
the National Taiwan University Hospital between
February 2007 and May 2008. Patients were eligi-
ble for the study if all of the following applied:
(1) male or female aged ≥ 18 years; (2) informed
consent had been obtained; (3) the patient was
willing and able to complete the micturition
diary correctly; (4) the OAB symptoms, including
urinary frequency, urgency, or urge incontinence,
had persisted for ≥ 3 months; (5) the patient must
have experienced frequency, defined as ≥ eight
micturitions per 24 hours. Exclusion criteria in-
cluded: (1) pregnant and lactating women or
those who intended to become pregnant during
the study; (2) clinically significant bladder out-
flow obstruction (such as men with benign pro-
static hyperplasia or women with bladder outlet
obstruction); (3) significant post-void residual
(PVR) volume (> 200 mL); (4) genuine stress uri-
nary incontinence; (5) evidence of symptomatic
urinary tract infection, chronic inflammation,
bladder stones, previous pelvic radiation ther-
apy, or previous or current malignant disease of
the pelvic organs; (6) patients with any medical
condition that contraindicated the use of anti-
muscarinic medication; (7) uncontrolled narrow
angle glaucoma, urinary or gastric retention, or
any other medical condition that, in the opinion
of the investigator, contraindicated the use of 
antimuscarinics.
Eligible patients were randomized to one of the
following two treatment groups: 5 mg solifenacin
once daily or 4 mg tolterodine once daily. At base-
line, a complete medical history, medication his-
tory, physical examination, urinalysis, and blood
test (complete blood count and routine biochem-
istry) were obtained. Patients were instructed to
complete a 3-day voiding diary as a baseline con-
dition before the intervention. Recorded items in
the voiding diary included times of micturition,
urgency and incontinence episodes, time of ris-
ing and going to bed, void volume of each mic-
turition, and numbers of pads used. A validated
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six-point categorical scale, the Patient Perception
of Bladder Condition (PPBC), was used to assess
the severity of OAB.15 Also, to evaluate the ad-
verse effect of dry mouth that either intervention
can cause, a visual analogue scale (VAS) was used
to assess its severity. The response to the treat-
ment was assessed with a three-point scale (not,
a little, and much improved) by patients and 
investigators.
Visits were scheduled at weeks 4, 8 and 12.
Patients were instructed to complete a 3-day void-
ing diary 3 days before each scheduled visit.
PPBC and VAS for dry mouth were evaluated at
each visit. All observed or spontaneously reported
adverse events were also recorded at each visit. PVR
volume was assessed by ultrasonography at the
visit at week 12.
From the diary data, we obtained the follow-
ing parameters: micturition numbers, urgency
episodes, incontinence episodes, and total vol-
ume voided per 24 hours. Mean volume voided
per micturition was calculated as the total voided
volume divided by the micturition number. The
primary efficacy endpoint was the change from
baseline to endpoint for the mean number of
micturitions per 24 hours. Secondary efficacy
endpoints included: (1) change from baseline to
endpoint for mean volume voided per micturi-
tion; (2) change from baseline to endpoint for
mean urgency episodes per 24 hours; (3) change
from baseline to endpoint for mean incontinence
episodes per 24 hours; (4) change from baseline
to endpoint for PPBC; and (5) patient and physi-
cian assessment of treatment benefit. Safety was
assessed by counting the incidence of adverse
events, by evaluating the change from baseline to
endpoint for patient assessment of dry mouth
symptoms (VAS), and measuring PVR volume.
Patients who took at least one dose of study
medication were included in the safety popula-
tion. Patients who took at least one dose of the
study medication and provided efficacy data at
baseline and endpoint visit were included in the
full analysis set. Patients in this set who com-
pleted the study without major deviations from
the protocol were included in the per protocol set
(PPS). All efficacy analyses were based on the PPS.
Changes from baseline to endpoint for mean mic-
turition number, mean urgency episodes, mean in-
continence episodes, and PPBC were compared
between the two treatment groups by Student’s 
t test. All safety analyses were based on the safety
population. Adverse events as recorded by the 
investigators were coded using the World Health
Organization Adverse Reaction Terminology cod-
ing system.16 Comparisons of incidence rates be-
tween the treatment groups were performed using
Fisher’s exact test. All statistical tests were two-
sided, with a significance level of α = 0.05.
Results
A total of 75 patients (25 men and 50 women)
were randomized into two group: 39 in the so-
lifenacin group (5 mg once daily) and 36 in the
tolterodine group (4 mg once daily). Two patients
in the tolterodine group withdrew from the study
without any efficacy assessment; three patients
in the solifenacin group and one in the toltero-
dine group did not complete the 12-week treat-
ment. Another patient in the solifenacin group
was prescribed with prohibited medication at the
beginning of the study. The above seven patients
were excluded from the efficacy analyses based
on the PPS.
The two treatment groups were not signifi-
cantly different in demographic data, including
age, sex, height, weight, comorbidity, concomitant
medication for comorbidity, and baseline OAB
parameters (Table 1). The Figure shows the efficacy
analyses at week 12. In primary efficacy analysis,
compared with the baseline, both treatment groups
demonstrated significant improvements in reduc-
ing mean micturition numbers per 24 hours from
week 4. At week 12, the mean changes from base-
line in micturition number per 24 hours were
not significantly different between the solifenacin
and tolterodine groups (–2.56 ± 3.31 vs. −2.44 ±
4.56, p=0.58). In secondary efficacy analyses, both
groups had significant improvements in reducing
urgency and incontinence episodes per 24 hours.
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At week 12, the mean changes from baseline
were not significant for urgency episodes be-
tween the solifenacin and tolterodine groups 
(−1.70 ± 3.07 vs. −1.15 ± 2.68, p = 0.37), nor were
the mean changes for incontinence episodes sig-
nificant for the solifenacin and tolterodine groups
(−2.79±2.82 vs. −4.67±9.29, p=0.28). Compared
with the baseline, a significant increase in mean
voided volume per micturition was only observed
in the solifenacin group (27.61 ± 51.74 mL), but
not in the tolterodine group (10.60 ± 50.29 mL).
The quality of life following treatment, as evaluated
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Figure. (A) Mean reductions in micturitions, urgency episodes,
and incontinence episodes per 24 hours after treatment for
12 weeks. (B) Mean changes in voided volume per micturition
after treatment for 12 weeks. (C) Mean changes in Patient
Perception of Bladder Condition scale after treatment for 
12 weeks.
Table 1. Demographics and overactive bladder parameters of the 75 patients
Variables Solifenacin (n = 39) Tolterodine (n = 36) p
Sex, female 26 (66.7) 24 (66.7) ns
Age (yr) 58.9 ± 15.1 55.3 ± 15.7 ns
Height (cm) 160.6 ± 7.1 158.8 ± 7.3 ns
Weight (kg) 63.4 ± 9.5 60.5 ± 11.0 ns
Baseline OAB parameters
Symptom duration (yr) 4.2 ± 6.2 4.4 ± 4.9 ns
Micturitions/24 hr 13.80 ± 4.95 13.69 ± 4.43 ns
Voided volume/micturition (mL) 145.10 ± 61.02 135.70 ± 47.43 ns
Urgency episodes/24 hr 4.57 ± 5.83 3.68 ± 4.45 ns
Incontinence episodes/24 hr 3.21 ± 3.05 6.19 ± 5.83 ns
Perceived bladder condition 3.9 ± 1.1 3.9 ± 1.2 ns
Prior drug therapy 18 (46.2) 20 (55.5) ns
Prior non-drug therapy 1 (2.6) 3 (8.3) ns
Patients had comorbidities 28 (71.8) 31 (81.6) ns
Patients received drugs for comorbidities 30 (76.9) 23 (63.9) ns
*Data presented as mean ± standard deviation or n (%). OAB = overactive bladder; ns = not significant.
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with PPBC, was significantly improved in both
groups. At week 12, the mean changes from base-
line in PPBC were −1.40 ± 1.40 and −1.40 ± 1.60
in the solifenacin and tolterodine groups, respec-
tively, and did not differ significantly between
the two groups (p = 0.72). Patient and physician
assessment of treatment benefit showed that im-
provements were achieved in the majority of 
patients in both groups, whereas the treatment
benefits were not significantly different between
the two groups (Table 2).
Table 3 shows the safety analyses: 15 (38.5%)
and nine (25.0%) patients in the solifenacin and
tolterodine group, respectively, suffered from at
least one adverse effect, and the percentages did
not differ between the two groups (p = 0.23). The
reported adverse effects included dry mouth, con-
stipation, hiccups, palpitations, and dizziness,
with the most common being dry mouth (18.0%
vs. 8.3%, p = 0.31) and constipation (12.8% vs.
2.8%, p = 0.20). Between the two groups, the in-
cidence of each adverse effect was not significantly
different (Table 3). One patient in the solifenacin
group withdrew from the study because of dizzi-
ness, and another in the tolterodine group with-
drew because of palpitations. The mean change
in dry mouth symptoms, as assessed by VAS, was
no different between the solifenacin and toltero-
dine groups (0.36 ± 2.71 vs. –0.01 ± 2.29, p = 0.56).
The change in PVR volume was small in the so-
lifenacin and tolterodine groups (0.60 ± 44.6 vs.
3.51 ± 2.26 mL, p = 0.18) and was not clinically
significant in either group.
Discussion
The present study was a prospective, randomized,
parallel study that compared the efficacy and
safety of 5 mg solifenacin once daily and 4 mg
tolterodine once daily. Although similar compar-
isons between the two antimuscarinics have been
made in western populations,13,14 this is believed
to be the first that was based on a Taiwanese
population. The major findings included: (1)
both medications were significantly effective in
reducing OAB symptoms (micturition frequency,
urgency episodes, and incontinence episodes);
(2) the efficacy appeared not to differ between
Table 3. Safety analyses of solifenacin and tolterodine
Variables Solifenacin (n = 39) Tolterodine (n = 36) p
Patients with AEs† 15 (38.5) 9 (25.0) 0.23
Patients who discontinued 1 (2.6) 1 (2.8) 1.00
Dry mouth 7 (18.0) 3 (8.3) 0.31
Constipation 5 (12.8) 1 (2.8) 0.20
Hiccup 1 (2.6) 0 (0) 1.00
Palpitation 1 (2.6) 1 (2.8) 1.00
Dizziness 1 (2.6) 0 (0) 1.00
Fatique 1 (2.6) 0 (0) 1.00
Changes in VAS of dry mouth 0.36 ± 2.71 –0.01 ± 2.29 0.56
Changes in PVR volume (mL) 0.60 ± 44.60 3.51 ± 2.26 0.18
*Data presented as mean ± standard deviation or n (%); †the severity grading was based on WHO-ART, all the AEs were mild or 
moderate in nature; no severe AEs developed in both groups. AE = adverse event; VAS = visual analog scale; PVR = post-void residual.
Table 2. Patient and physician assessment of
treatment benefit
Solifenacin Tolterodine
By patients (%)
Not improved 5.7 15.2
Little improved 77.1 57.6
Much improved 17.1 27.3
By physicians (%)
Not improved 5.7 12.1
Little improved 62.9 66.7
Much improved 31.4 21.2
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the two groups; (3) the most common adverse
effects were dry mouth and constipation; and (4)
all the adverse effects were mild to moderate in
nature, and discontinuation because of adverse
effects was rare.
Normal bladder contraction is mediated
through stimulation of muscarinic receptors (sub-
types M1–M5) in the detrusor muscle.17 Although
M2 receptors predominate in number, normal
bladder contraction is mainly mediated by M3 
receptors.9 As the mainstay of treatment for OAB,
antimuscarinics are thought to act on muscarinic
receptors and therefore inhibit bladder contrac-
tion.8 In addition, muscarinic receptors have also
been found in urothelial and suburothelial cells.18
Although their roles have not been entirely es-
tablished, they might have a role in afferent sig-
naling.19 Increasing evidence suggests that the
therapeutic action of antimuscarinics is associ-
ated with bladder sensation, rather than bladder
contractility.20 The exact mechanism still requires
further investigation.
Comparisons of solifenacin and tolterodine
have been conducted in western populations.13,14
Chapple et al14 conducted a multicenter random-
ized trial of 1281 OAB patients, of whom 1077
were treated. After placebo run-in, patients were
randomized into four treatment groups with
tolterodine (2 mg twice daily), solifenacin (5 mg
daily), solifenacin (10 mg daily), or placebo for 
a 12-week treatment period. Compared with
placebo, all the three treatment groups demon-
strated a significant decrease in the mean num-
ber of micturitions per 24 hours and a significant
increase in the mean voided volume per micturi-
tion. However, a significant decrease in the mean
number of urgency and incontinence episodes
was only observed in the solifenacin groups, and
not in the tolterodine group. The subsequent
Solifenacin and Tolterodine as an Active com-
parator in a Randomized (STAR) trial, tested the
efficacy of a flexible dose of solifenacin.13 Patients
could increase their dose of solifenacin from 5 mg
to 10 mg after 4 weeks of treatment. Patients in the
tolterodine group (4 mg) were escalated to 4 mg
tolterodine plus 4 mg placebo. Both medications
demonstrated similar efficacy in reducing mic-
turition frequency. However, solifenacin showed
greater efficacy in decreasing urgency episodes,
incontinence, urge incontinence, and pad usage.
More patients in the solifenacin group became
continent and reported improvements. In both
groups, the majority of adverse effects were mild
to moderate in nature, and the discontinuation
rates were comparable and low. These findings
suggest that solifenacin and tolterodine are effec-
tive in treating OAB symptoms. Furthermore, with
a flexible dosing regimen, solifenacin could be
superior to tolterodine with regard to the major-
ity of the efficacy variables.
The major adverse effects of antimuscarinic
agents include dry mouth, constipation, and
blurred vision.21,22 It is these adverse effects that
limit the clinical use of antimuscarinics. The num-
ber of adverse effects reported in our trial was gen-
erally in line with previous studies.13,14 In the
present study, the incidence of adverse effects was
not significantly different between the two groups.
All the adverse effects were mild to moderate in
nature, and only one patient in each group dis-
continued their treatment because of intolerability.
These findings suggest that both solifenacin and
tolterodine are well tolerated. Clinically, another
factor that limits the use of antimuscarinic agents
is the consideration that detrusor contraction
might be inhibited and urinary retention could
develop. In our series, none experienced urinary
retention after taking either tolterodine or solife-
nacin, suggesting that both drugs can be safely
used in patients without evidence of bladder out-
let obstruction and with a limited residual vol-
ume (< 200 mL). In fact, there is little evidence to
show that antimuscarinics significantly reduce
detrusor contraction during the voiding phase.8
This is because antimuscarinics mainly act dur-
ing the storage phase, when there is normally no
parasympathetic activity.20 Furthermore, most an-
timuscarinics are competitive drugs. During the
voiding phase, when there is a massive release of
acetylcholine, the effects of these drugs are de-
creased. Although a high dose of antimuscarinic
drugs inevitably causes urine retention, clinically,
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there is little evidence that these drugs cause urine
retention at their commercial doses.8
The major limitation of the present study, in
comparison with previous studies in western coun-
tries,13,14 was the relatively small patient number.
This could have decreased the power for detecting
a difference between the two medications. How-
ever, the present study is still valuable in providing
experience in the use of both drugs in a Taiwanese
population, which has been rarely reported before.
Another limitation was that only a few patients re-
corded their voids at bedtime. Therefore, the effects
on reducing nocturia could not be analyzed.
In conclusion, solifenacin and tolterodine dem-
onstrated significant efficacy in treating key OAB
symptoms, including urinary frequency, urgency,
and incontinence. The efficacy was equal between
the two drugs. The most common adverse effects
were dry mouth and constipation, and all the ad-
verse effects were mild to moderate in severity.
Discontinuation rates because of adverse effects
were low. These findings suggest that both solife-
nacin and tolterodine can be effective and safe in
treating OAB in Taiwanese populations.
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